Common questions
Mazdutide — questions, answered plainly.
6 research-context questions about Mazdutide. Answers stay neutral and reference what is published in the peer-reviewed literature — no dosing, no human-use guidance, no extrapolation beyond what the cited studies report.
- 01
What is mazdutide?
Mazdutide (IBI362, originally LY3305677) is a once-weekly dual GLP-1 and glucagon receptor agonist. Originally licensed from Eli Lilly to Innovent Biologics, it is most extensively studied in Chinese populations.
- 02
Where is mazdutide approved?
Mazdutide has received conditional approval in China for chronic weight management. It is not FDA-approved (US) or EMA-approved (EU) at the time of writing.
- 03
How does mazdutide differ from semaglutide and tirzepatide?
Semaglutide is a GLP-1 agonist. Tirzepatide is a GIP + GLP-1 dual agonist. Mazdutide is a GLP-1 + glucagon dual agonist, sharing its dual-receptor framework with survodutide rather than tirzepatide.
- 04
What did the Phase 3 Chinese mazdutide trial show?
Ji et al. 2025 (NEJM, PMID 40421736; n=610) reported dose-dependent body-weight reductions up to 14.01% versus placebo over the trial period in Chinese adults with obesity or overweight.
- 05
Does mazdutide work in non-Asian populations?
The cited primary trials all enrolled Chinese populations. Generalisability to non-Asian populations is not established in the published literature. International Phase III studies in broader populations are needed.
- 06
What are the limits of the mazdutide evidence?
Regulatory status is jurisdiction-specific (conditional China approval only). All primary published trials enrolled Chinese populations. Long-term cardiovascular and safety outcomes have not been established.
Important
These answers are not medical advice.
Mazdutide is referenced in research literature only. Palthera does not provide dosage, cycling, stacking, or injection guidance, and content is not intended to support consumer or therapeutic use. Speak to a qualified clinician for any health decisions.